Table 3.
Residual BZD agonist plasma concentrations in the melatonin (CRM) and placebo groups, at baseline and at month 1
| Study group BZD use | Residual concentrations (ng ml−1) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Month 1 | |||||||
| n | (%) | Median | [Range] | n | (%) | Median | [Range] | |
| CRM group | 46 | 45 | ||||||
| Non-users | 0 | (0) | 0.0 | 31 | (69) | 0.0 | ||
| Temazepam | 9 | (20) | 1070 | [438–2160] | 5 | (11) | 517 | [24.0–1210] |
| Zopiclone | 23 | (50) | 97.8 | [5.2–1030] | 6 | (13) | 32.4 | [1.5–169] |
| Zolpidem | 14 | (30) | 13.6 | [1.1–40.0] | 3 | (7) | 3.2 | [1.0–56.1] |
| Placebo group | 46 | 45 | ||||||
| Non-users | 0 | (0) | 0.0 | 39 | (87) | 0.0 | ||
| Temazepam | 5 | (11) | 704 | [0–968] | 1 | (2) | 15.1 | [15.1–15.1] |
| Zopiclone | 29 | (63) | 138 | [0–518] | 4 | (9) | 19.5 | [6.0–296] |
| Zolpidem | 12 | (26) | 17.3 | [5.2–46.1] | 1 | (2) | 12.3 | [12.3–12.3] |